Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis

Adial Pharmaceuticals has changed its name to Azora Therapeutics and its Nasdaq ticker to "AZR" effective October 29, 2026, following the June 2026 acquisition of Azora Therapeutics. Stockholders approved conversion of the Series A preferred stock issued in the acquisition into common stock, and a new executive team was installed, led by co-founder and CEO Matt Davidson, Ph.D. The pipeline is now centered on AT177, an oral colon-targeted AhR agonist for ulcerative colitis, with a Phase 1 trial expected in the first half of 2027. The June 2026 private placement raised roughly $32 million, with another $32 million possible upon Phase 1 initiation, funding operations into 2028.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.